CVS Health Corp. (CVS) Cash Flow Statement

The sequential improvement in operating cash flow suggests that the company is collecting premiums faster than it is paying claims, a key driver of float. This rebound follows a weak 2025Q3 when operating cash flow was only $796M, indicating that the underwriting cycle may be turning favorable. However, the sustainability of this trend depends on medical utilization remaining contained, as elevated utilization could quickly erode this cash generation.

The rising claims payments are consistent with the elevated medical utilization trends noted in the income statement analysis. While the company's combined ratio improved to 95.6% in 2026Q2, the absolute dollar increase in claims payments suggests that the improvement may be driven by premium growth rather than cost containment. Investors should monitor whether claims inflation continues to outpace premium growth, which could pressure future cash flows.

The modest net investment outflow of $1.2B in 2026Q2 suggests that CVS is not aggressively repositioning its investment portfolio. This is consistent with a conservative approach to managing the float, focusing on liquidity and income rather than capital gains. Given the company's high leverage, maintaining a stable investment portfolio may be prudent, but it also means that investment income is unlikely to be a major source of cash flow growth.

The dividend payout ratio based on operating cash flow is approximately 14%, indicating a comfortable coverage. However, the absence of share repurchases suggests that management is prioritizing debt reduction or other uses of cash over returning capital to shareholders. This is a prudent approach given the strained balance sheet, but it may signal limited confidence in the stock's valuation or a need to conserve cash for upcoming debt maturities.

The high OCF/NI ratio suggests that earnings are backed by actual cash inflows, which is a positive sign for earnings quality. However, the 2025Q3 net loss of $4.0B with positive operating cash flow of $796M indicates that non-cash charges, such as impairments or reserve adjustments, may have weighed on earnings. This divergence warrants attention, as it may imply that the company's reported earnings are not fully reflective of its cash-generating ability.